会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
    • 取代的4-(4-哌啶-4-基 - 哌嗪-1-基) - 氮杂环庚烷衍生物及其作为神经激肽拮抗剂的用途
    • US20060058285A1
    • 2006-03-16
    • US10540456
    • 2003-12-17
    • Frans JanssensFrancois SommenBenoit Christian De BoeckJoseph Leenaerts
    • Frans JanssensFrancois SommenBenoit Christian De BoeckJoseph Leenaerts
    • A61K31/55C07D403/14
    • C07D401/12C07D401/14C07D405/14C07D413/14
    • The invention concerns substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of pain, emesis, anxiety, depression and IBS. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1. In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P and Neurokinin B by blocking the NK1, NK2 and NK3 receptors, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of tachykinin-mediated conditions, such as, for instance CNS disorders, in particular schizoaffective disorders, depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions; inflammation; allergic disorders; emesis; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders; vasospastic diseases; fibrosing and collagen diseases; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.
    • 本发明涉及具有神经激肽拮抗活性的取代的4-(4-哌啶-4-基 - 哌嗪-1-基) - 氮杂环庚烷衍生物,特别是NK 1拮抗活性,其制备方法,包含它们的组合物和 它们用作药物,特别是用于治疗疼痛,呕吐,焦虑,抑郁和我
    • 7. 发明申请
    • Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives
    • 基于阿片样物质治疗疼痛的新型制剂包括取代的1,4-二哌啶-4-基 - 哌嗪衍生物
    • US20060128721A1
    • 2006-06-15
    • US10560476
    • 2004-06-07
    • Frans JanssensFrancois SommenBenoit Christian Albert Ghislain De BoeckJoseph Elisabeth LeenaertsYves Emiel, Maria Van RoosbroeckTheo Frans Meert
    • Frans JanssensFrancois SommenBenoit Christian Albert Ghislain De BoeckJoseph Elisabeth LeenaertsYves Emiel, Maria Van RoosbroeckTheo Frans Meert
    • A61K31/496
    • A61K45/06A61K31/496A61K31/551A61K2300/00
    • This invention concerns novel formulations for opioid-based treatments of pain and/or nociception comprising opioid analgesics and 1,4-di-piperidin-4-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, the use of said formulation for the manufacture of a medicament for the prevention and/or treatment of emesis, pain and/or nociception, in particular in opioid-based acute and chronic pain treatments, more in particular in inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments and the use of an NK1-receptor antagonist for the manufacture of a medicament for the prevention and/or treatment of respiratory depression in opioid-based treatments of pain. The pharmaceutical formulations according to the invention comprise a pharmaceutically acceptable carrier and, as active ingredients, a therapeutically effective amount of an opioid analgesic and NK1-antagonists according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1. The pharmaceutical composition according to the invention reduces to a large extent a number of unwanted side-effects associated with opioid analgesics, in particular emesis, respiratory depression and tolerance, thereby increasing the total tolerability of said opioids in pain treatment.
    • 本发明涉及用于基于阿片样物质治疗疼痛和/或伤害感受的新制剂,其包含具有神经激肽拮抗活性的阿片类镇痛药和1,4-二哌啶-4-基 - 哌嗪衍生物,特别是NK1 拮抗活性,所述制剂用于制备用于预防和/或治疗呕吐,疼痛和/或伤害感受,特别是基于阿片样物质的急性和慢性疼痛治疗的药物的用途,特别是在炎性, 手术,急诊室(ER),突破性,神经病理性和癌症疼痛治疗,以及使用NK 1受体拮抗剂制备用于预防和/或治疗阿片样物质中呼吸抑制的药物 的治疗疼痛。 根据本发明的药物制剂包含药学上可接受的载体,并且作为活性成分,具有治疗有效量的根据通式(I)的药学上可接受的酸的阿片样物质止痛剂和NK 1拮抗剂 或其碱加成盐,其立体化学异构形式,其N-氧化物形式和其前药,其中所有取代基如权利要求1中所定义。根据本发明的药物组合物在很大程度上降低了多个不需要的副产物, 与阿片类止痛药相关的作用,特别是呕吐,呼吸抑制和耐受性,从而增加所述阿片类药物在疼痛治疗中的总耐受性。